Arcturus Therapeutics

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

Retrieved on: 
화요일, 11월 1, 2022
Nephrology, Arcturus Therapeutics, RNA transfection, Influenza, Degenerative disease, Vaccination, Hospital, CSL Behring, Mortality, ARCT, Research, Industry, Antibody, COVID-19, Risk, Disease, Dialysis, CSL, R, Death, Public health, Immunodeficiency, Vaccine, Influenza A virus, NASDAQ, United, Therapy, CSL Limited, ASX, H5N1, History, Patient, Iron deficiency, Haemophilia, CDC, Severe acute respiratory syndrome coronavirus 2, Biotechnology, Center, Infection, Ageing, Arcturus

KING OF PRUSSIA, Pa., Nov. 1, 2022 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus Therapeutics") to access their late stage self-amplifying mRNA (sa-mRNA) vaccine platform technology.

Key Points: 
  • KING OF PRUSSIA, Pa., Nov. 1, 2022 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus Therapeutics") to access their late stage self-amplifying mRNA (sa-mRNA) vaccine platform technology.
  • Arcturus Therapeutics (NASDAQ: ARCT) is currently developing next generation mRNA vaccines.
  • These combined capabilities will accelerate our journey in mRNA," said CSL Chief Operating Officer Paul McKenzie.
  • Today, CSL including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor provides lifesaving products to patients in more than 100 countries and employs 30,000 people.

Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response

Retrieved on: 
수요일, 8월 31, 2022
COVID-19, Infectious Diseases, FDA, Clinical Trials, Public Policy, Government, Biotechnology, Pharmaceutical, Health, Public Policy, Other Policy Issues, COVID-19, Contract, CEO, Technology, RNA, OTC, Janssen Pharmaceuticals, Liver, Government, Therapy, Arcturus Therapeutics, Gene editing, Vaccine, Kirkbi AG v Ritvik Holdings Inc, Cystic Fibrosis Foundation, Disease, Risk, ARCT, MicroRNA, BARDA, LinkedIn, Department, DNA, SEC, Biomedical Advanced Research and Development Authority, Infection, Cystic fibrosis, Patent, National Strategy for Trusted Identities in Cyberspace, Hepatitis B, Severe acute respiratory syndrome coronavirus 2, Intention, Nasdaq, Assistant, Twitter, III, Johnson & Johnson, Annual report, RNA transfection, Private Securities Litigation Reform Act, Development, Glycogen storage disease type III, Arcturus

The award provides $63.2 million over three years to support preclinical, manufacturing, nonclinical safety studies, along with development and regulatory support for Arcturus self-amplifying mRNA vaccine platform technology for rapid pandemic influenza response through Phase 1 clinical studies.

Key Points: 
  • The award provides $63.2 million over three years to support preclinical, manufacturing, nonclinical safety studies, along with development and regulatory support for Arcturus self-amplifying mRNA vaccine platform technology for rapid pandemic influenza response through Phase 1 clinical studies.
  • We are very pleased to have won this substantial award from the BARDA and look forward to working with the U.S. government to support the development of our proprietary self-amplifying mRNA vaccine technology for rapid pandemic influenza response.
  • These are qualities that are essential to a rapid response against pandemic influenza and are consistent with strategic objectives of the U.S. governments National Strategy for Pandemic Influenza.
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.

Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

Retrieved on: 
목요일, 8월 18, 2022
Health, Infectious Diseases, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Janssen Pharmaceuticals, Liver, III, Multimedia, Johnson & Johnson, Cystic Fibrosis Foundation, CEO, Diagnosis, Messenger RNA, Private Securities Litigation Reform Act, ARCT, SEC, Clinical trial, Glycogen storage disease type III, Infection, MNT, Patent, Annual report, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Gene editing, DNA, Therapy, COVID-19, Twitter, Cystic fibrosis, Vaccine, OTC, RNA, C.I, Safety, Risk, Intention, Vaccination, Arcturus Therapeutics, MicroRNA, Hepatitis B virus, Nasdaq, Severe acute respiratory syndrome coronavirus 2, LinkedIn, RNA transfection, Omicron, Arcturus

In Figure B, three additional participants with suspected asymptomatic seroconversion were removed from the day 181 analysis (n=6, day 181).

Key Points: 
  • In Figure B, three additional participants with suspected asymptomatic seroconversion were removed from the day 181 analysis (n=6, day 181).
  • Neutralizing antibody responses against Omicron variants BA.1, BA.2, and BA.5 were measured at the Moore Lab in South Africa.
  • These data show sustained neutralizing responses to antigenically distinct variants of concern, including Omicron BA.5, for at least six months after vaccination.
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.

Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress

Retrieved on: 
화요일, 8월 9, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Liver, Multimedia, RH, CEO, EUA, ARCT, Clinical trial, COVID, Clinical, Infection, MNT, Research, Diversified Specialty Institute Holdings, Inc., MOH, Patient, Therapy, Company, Chemistry, Cystic fibrosis, European Securities and Markets Authority, Vaccine, Biotechnology, Transport, OTC, RNA, Interval (mathematics), RT, Ornithine transcarbamylase deficiency, Vaccination, Arcturus Therapeutics, News, Nasdaq, Royal commission, CMC, European Commission, RNA transfection, Temperature, Pharmaceutical industry, Cryptocurrency, Online gambling, Omicron, Arcturus

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Arcturus Therapeutics, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the second quarter ended June 30, 2022, and provided corporate updates.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Arcturus Therapeutics, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the second quarter ended June 30, 2022, and provided corporate updates.
  • (Graphic: Business Wire)
    Arcturus continues to demonstrate increasing value of our next generation mRNA vaccine and therapeutic platforms, said Joseph Payne, President and CEO of Arcturus Therapeutics.
  • Arcturus expects a registrational booster study for ARCT-154 to begin in Q4 2022.
  • Based on the current pipeline, the Companys cash position is expected to be sufficient to support operations into late 2023.

Global Pharmaceutical Contract Manufacturing and Research Services Market 2022-2030: Drug Shortage Driving Demand for Pharmaceutical Development & Commercial Success of Biologics for Clinical Use - ResearchAndMarkets.com

Retrieved on: 
화요일, 5월 24, 2022
Health, Pharmaceutical, API, Population, Conditional sentence, GeoVax, CATO, Investment, Vaccine, Therapy, Clinical trial, USD, Arcturus, COVID-19, Active ingredient, CRO, Ageing, CAGR, Growth, Cancer, Prevalence, Arcturus Therapeutics, Fine chemical, Renewable energy, Pharmaceutical industry, Research

The "Pharmaceutical Contract Manufacturing and Research Services Market Size, Share & Trends Analysis Report by Service (Manufacturing, Research), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmaceutical Contract Manufacturing and Research Services Market Size, Share & Trends Analysis Report by Service (Manufacturing, Research), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global pharmaceutical contract manufacturing and research services market size is expected to reach USD 395.2 billion by 2030.
  • Outsourcing allows pharmaceutical companies to focus on their core competencies such as sales and marketing rather than manufacturing and research.
  • The COVID-19 pandemic has provided new opportunities for pharmaceutical contract manufacturing and research services.

Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

Retrieved on: 
목요일, 5월 5, 2022
Infectious Diseases, Pharmaceutical, Health, Clinical Trials, COVID-19, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Cystic fibrosis, Private Securities Litigation Reform Act, Omicron, Nasdaq, Messenger RNA, Twitter, CureVac, RNA, Company, MicroRNA, Time, Janssen Pharmaceuticals, HBV, Johnson & Johnson, Glycogen storage disease type III, COVID, Duke–NUS Medical School, Clinical trial, OTC, Gene editing, MNT, III, Risk, Annual report, GSD, Therapy, Patent, CRO, DNA, D614G, Multimedia, Cystic Fibrosis Foundation, Severe acute respiratory syndrome coronavirus 2, Beta, Vaccine, Arcturus Therapeutics, LinkedIn, Intention, NASH, Infection, Fatty liver disease, Liver, Takeda Pharmaceutical Company, SEC, Vaccination, RNA transfection, CEO, Hepatitis B virus, ARCT, Interval (mathematics), Arcturus, Infectious Diseases, Pharmaceutical, Health, Clinical Trials

These results provide additional validation of Arcturus next generation STARR mRNA technology for vaccines.

Key Points: 
  • These results provide additional validation of Arcturus next generation STARR mRNA technology for vaccines.
  • Samples from the trial will be further analyzed for neutralizing antibody activity against different strains of SARS-CoV-2, including the Omicron lineage.
  • The Company has initiated start-up activities with an international CRO toward a pivotal Phase 3 booster trial intended to support global registration.
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.

Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

Retrieved on: 
금요일, 3월 25, 2022
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Research, Infectious Diseases, Hospitals, Genetics, Science, Clinical Trials, ARCT, CureVac, Hepatitis B virus, Therapy, Janssen Pharmaceuticals, LinkedIn, Fatty liver disease, Duke–NUS Medical School, DNA, Patent, III, Cystic fibrosis, Vaccine, Liver, Messenger RNA, Conference, CEO, RNA, Severe acute respiratory syndrome coronavirus 2, MicroRNA, NASH, Infection, Gene editing, Twitter, RNA transfection, Glycogen storage disease type III, Nasdaq, COVID-19, Diversified Specialty Institute Holdings, Inc., Cystic Fibrosis Foundation, Takeda Pharmaceutical Company, OTC, Arcturus Therapeutics, Johnson & Johnson, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Research, Infectious Diseases, Hospitals, Genetics, Science, Clinical Trials

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President and CEO of Arcturus Therapeutics, will participate in a panel discussion titled RNA Therapeutics in Rare Diseases at the Cantor Fitzgerald Virtual rare Disease Summit on Barclays Global Healthcare Conference on Tuesday, March 29, 2022 at 2:45 p.m.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President and CEO of Arcturus Therapeutics, will participate in a panel discussion titled RNA Therapeutics in Rare Diseases at the Cantor Fitzgerald Virtual rare Disease Summit on Barclays Global Healthcare Conference on Tuesday, March 29, 2022 at 2:45 p.m.
  • Those interested in participating in the Cantor Fitzgerald Virtual Rare Disease Summit are encouraged to contact their Cantor Fitzgerald representative.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress

Retrieved on: 
월요일, 2월 28, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, NHP, RNA transfection, ARCT, Omicron, File, Diversified Specialty Institute Holdings, Inc., Ornithine transcarbamylase deficiency, RNA, Research, Therapy, Infection, Safety, Cystic fibrosis, OTC, CMC, Review, Vaccine, Severe acute respiratory syndrome coronavirus 2, Biotechnology, EUA, Liver, Nasdaq, Arcturus Therapeutics, Patient, CTA, CEO, Vaccination, Pharmaceutical industry, Animal, Arcturus, Health

LUNAR-COV19; ARCT-154: Arcturus collaborator Vinbiocare has completed filing of an application for EUA with the Vietnam Ministry of Health.

Key Points: 
  • LUNAR-COV19; ARCT-154: Arcturus collaborator Vinbiocare has completed filing of an application for EUA with the Vietnam Ministry of Health.
  • In January 2022, Arcturus announced data from Phase 1/2 clinical development programs for ARCT-154 and ARCT-165 used as boosters following primary vaccination with Comirnaty.
  • Total revenue for the year ended December 31, 2021 was $12.4 million compared with $9.5 million for the year ended December 31, 2020.
  • Based on the current pipeline, the Companys cash position is expected to be sufficient to support operations into late 2023.

Avidity Biosciences Appoints Steve Hughes, M.D., as Chief Medical Officer

Retrieved on: 
수요일, 2월 23, 2022
Therapy, Twitter, Degenerative disease, RNA, MARINA, Security (finance), FSHD, Biogen, AOC, Imperial College Business School, Drug development, Private Securities Litigation Reform Act, CSL Behring, U.S. Securities and Exchange Commission, Antibody-oligonucleotide conjugate, DM1, LinkedIn, Ionis Pharmaceuticals, Science, AOCS, Leadership, Imperial College London, SAN, Nasdaq, MBA, Arcturus Therapeutics, Data management, Patient, CMO, Neurology, DMD, SEC, Pharmaceutical industry, Organovo, Sanofi, Avidity, Arcturus

Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams at prominent biopharmaceutical companies.

Key Points: 
  • Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams at prominent biopharmaceutical companies.
  • "Steve brings a unique combination of extensive experience in the RNA field as well as a deep understanding of rare disease drug development," said Sarah Boyce, president and chief executive officer.
  • The AOC platform is a ground-breaking technology that significantly broadens the potential for RNA therapies," said Steve Hughes, M.D., chief medical officer at Avidity.
  • Dr. Hughes's previous positions include the Chief Clinical Development Officer at Ionis Pharmaceuticals and positions at Biogen, CSL Behring and Sanofi.

Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial

Retrieved on: 
화요일, 1월 25, 2022
Research, Infectious Diseases, FDA, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Other Science, COVID-19, Private Securities Litigation Reform Act, Cystic Fibrosis Foundation, RNA, ARCT, National Institute, Duke–NUS Medical School, Vaccination, Gene editing, Infection, Liver, Nasdaq, CureVac, Johnson & Johnson, NASH, MicroRNA, Fatty liver disease, RNA transfection, ID50, COVID, Janssen Pharmaceuticals, Company, Severe acute respiratory syndrome coronavirus 2, MNT, III, CEO, Takeda Pharmaceutical Company, University, OTC, Therapy, Intention, Annual report, Messenger RNA, HBV, Risk, Cystic fibrosis, Twitter, GSD, Hepatitis B virus, LinkedIn, Safety, DNA, Omicron, Patent, Interval (mathematics), Arcturus Therapeutics, Diversified Specialty Institute Holdings, Inc., Multimedia, SEC, Glycogen storage disease type III, Vaccine, Arcturus

View the full release here: https://www.businesswire.com/news/home/20220125005602/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220125005602/en/
    Figure 1: Pseudovirus (Omicron variant, research use) MNT assay results.
  • The multiples are fold rises of neutralizing antibody titers on Day 29 over Day 1 values.
  • All participants in the booster trial were below 65 years of age at the time of receiving the booster dose.
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.